Abuse Tobacco, Exposure
Conditions
Brief summary
This study evaluates how synthetic cooling additives like WS-3 and WS-23 impact e-cigarette perceptions, use behavior, and toxicant exposure.
Detailed description
PRIMARY OBJECTIVES: I. Assess the abuse liability of e-liquids with and without the presence of synthetic cooling agents. II. Determine the impact of synthetic cooling agents and flavor on EC puffing behavior (topography). III. Determine the exposure ranges (harmful and potentially harmful constituents \[HPHCs\], other toxicants) from vaping e-liquids with and without the presence of synthetic cooling agents. OUTLINE: Participants attend 4 sessions where they receive 1 of 4 randomly assigned flavored e-cigarettes. Participants use the e cigarettes for vaping followed by ad libitum vaping. Participants also complete surveys and undergo biosample collection throughout the study.
Interventions
BEHAVIORALBehavioral Intervention
Receive and use flavored e-cigarettes (EC) as directed
OTHERBiospecimen Collection
Undergo biosample sample collection
OTHERSurvey Administration
Complete surveys
Sponsors
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Subject, Outcomes Assessor)
Masking description
Participants and study staff will be blinded to the study conditions delivered at each visit.
Intervention model description
Randomization to condition order will be completed prior to study Visit 1. Each participant will receive a randomized ordering developed using a random sequence generator. Participants and data collection staff will be blinded to the order/conditions administered at each trial. The sequence list and subsequent participant ID numbers will be kept separate from data collection staff and will only be accessible by staff who will not be interacting with participants.
Eligibility
Sex/Gender
ALL
Age
21 Years to 29 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 21-29 years * Current e-cigarette (EC) user (defined as ≥ weekly use over the past 3 months) * Willing to provide informed consent and abstain from using their EC at least 12 hours prior to the four lab sessions * Read and speak English
Exclusion criteria
* Recently COVID-19+ (defined as positive test in the past 30 days) or a recent COVID-19 hospitalization (defined as a hospitalization within the past 6 months) * Unstable or significant psychiatric conditions (past and stable conditions will be allowed) * History of cardiac event or distress within the past 3 months * Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test) * Have suffered from any serious lung disease or infection (e.g. , tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days * Have hemophilia or another type of bleeding disorder * Are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Satisfaction and psychological reward | Minute 5 of vaping session, Minute 35 of vaping session | Satisfaction and psychological reward of e-cigarette (EC) vaping will be measured by the Modified Cigarette Evaluation Questionnaire (mCEQ). The mCEQ asks questions relating to satisfaction of using e-cigarettes on a scale from 0 (Not at all) - 6 (Extremely). |
| Sensory perceptions of EC vaping experience | Pre-vaping session | Sensory perceptions of EC vaping will be measured by the Sensory E-cigarette Expectancies Scale (SEES) questionnaire. The SEES asks questions about sensory experiences associated with vaping on a scale from 0 (Never) - 4 (Almost Always). |
| E-cigarette puff topography | 35 Minute Vaping session | Will be measured with a topography device that records frequency, duration, and flow rate of EC puffs. These measures are combined to inform overall EC puff behavior. |
| Levels of HPHC and other toxicant exposure from vaping e-liquids | After completion of sessions, estimated 4 years | Topography data collected for all participants for each of the conditions vaped will be averaged to produce four human-derived puffing regimens. Machine vaping will be conducted for each of the four e-liquids using the associated human-derived puffing regimens to determine the range of HPHCs and other toxicants in mainstream EC vapor. |
| Appeal and Sensory | Minute 5 of vaping session, Minute 35 of vaping session | Participants will rate appeal (e.g., liking, disliking) and sensory attributes (e.g., harshness, coolness) outcomes on Visual Analogue Scales (range, 0-100). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Economic demand breakpoint | Minute 35 of vaping session | The price point at which a participant is no longer willing to pay for a puff of the study e-liquid will be determined by an EC purchase task questionnaire. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAlayna P Tackett, PhD
Ohio State University Comprehensive Cancer Center
Outcome results
None listed